Patents Assigned to Jazz Pharmaceuticals Ireland Limited
-
Patent number: 11077079Abstract: The present application relates to GHB formulations and methods for manufacturing the same.Type: GrantFiled: December 10, 2020Date of Patent: August 3, 2021Assignee: Jazz Pharmaceuticals Ireland LimitedInventors: Clark Allphin, Scott Bura
-
Patent number: 11072579Abstract: The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.Type: GrantFiled: March 20, 2019Date of Patent: July 27, 2021Assignees: Jazz Pharmaceuticals Ireland Limited, SK Biopharmaceuticals Co., Ltd.Inventors: Moise A. Khayrallah, Gary Bream, Stephen E. Butts
-
Publication number: 20210212970Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.Type: ApplicationFiled: March 29, 2021Publication date: July 15, 2021Applicant: Jazz Pharmaceuticals Ireland LimitedInventor: Mark ELLER
-
Publication number: 20210128502Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.Type: ApplicationFiled: November 10, 2020Publication date: May 6, 2021Applicant: Jazz Pharmaceuticals Ireland LimitedInventor: Mark ELLER
-
Publication number: 20210121423Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: ApplicationFiled: December 22, 2020Publication date: April 29, 2021Applicant: Jazz Pharmaceuticals Ireland LimitedInventors: Clark P. Allphin, Gunjan Junnarkar, Roman Skowronski, Cuiping Chen, Katayoun Zomorodi, Mark Eller, Philip McGarrigle
-
Patent number: 10959976Abstract: The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders. The invention further relates to the development of methods for treating excessive sleepiness in a subject, e.g., due to narcolepsy or obstructive sleep apnea, with the surprising outcome that “normal” levels of wakefulness are achieved based on standard objective and subjective sleepiness tests.Type: GrantFiled: June 1, 2018Date of Patent: March 30, 2021Assignee: Jazz Pharmaceuticals Ireland LimitedInventors: Lawrence Patrick Carter, Yuan Lu, Katayoun Zomorodi
-
Patent number: 10940133Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.Type: GrantFiled: March 19, 2020Date of Patent: March 9, 2021Assignee: Jazz Pharmaceuticals Ireland LimitedInventor: Katayoun Zomorodi
-
Patent number: 10912754Abstract: The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders. The invention further relates to the development of methods for treating excessive sleepiness in a subject, e.g., due to narcolepsy or obstructive sleep apnea, with the surprising outcome that “normal” levels of wakefulness are achieved based on standard objective and subjective sleepiness tests.Type: GrantFiled: May 19, 2020Date of Patent: February 9, 2021Assignee: Jazz Pharmaceuticals Ireland LimitedInventors: Lawrence Patrick Carter, Yuan Lu, Katayoun Zomorodi
-
Patent number: 10864181Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.Type: GrantFiled: January 10, 2019Date of Patent: December 15, 2020Assignee: Jazz Pharmaceuticals Ireland LimitedInventor: Mark Eller
-
Patent number: 10829443Abstract: The present invention relates to a newly identified solvate form of (i?)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention further relates to methods of producing APC hydrochloride with increased purity.Type: GrantFiled: September 6, 2017Date of Patent: November 10, 2020Assignees: Jazz Pharmaceuticals Ireland Limited, SK Biopharmaceuticals Co., Ltd.Inventors: Jennifer Leigh Nelson, Fionn Hurley
-
Publication number: 20200338029Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: ApplicationFiled: May 12, 2020Publication date: October 29, 2020Applicant: Jazz Pharmaceuticals Ireland LimitedInventors: Clark P. Allphin, Michael DesJardin
-
Patent number: 10710958Abstract: The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.Type: GrantFiled: October 6, 2017Date of Patent: July 14, 2020Assignee: Jazz Pharmaceuticals Ireland LimitedInventors: Fionn Hurley, Lawrence Patrick Carter
-
Patent number: 10675258Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: GrantFiled: December 21, 2018Date of Patent: June 9, 2020Assignee: Jazz Pharmaceuticals Ireland LimitedInventors: Clark P. Allphin, Michael DesJardin
-
Publication number: 20200113853Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: ApplicationFiled: September 18, 2019Publication date: April 16, 2020Applicant: Jazz Pharmaceuticals Ireland LimitedInventors: Clark P. Allphin, Gunjan Junnarkar, Roman Skowronski, Cuiping Chen, Katayoun Zomorodi, Mark Eller, Philip McGarrigle
-
Patent number: 10512609Abstract: The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.Type: GrantFiled: December 19, 2018Date of Patent: December 24, 2019Assignee: Jazz Pharmaceuticals Ireland LimitedInventors: Clark Patrick Allphin, Edwin Gerard Walsh
-
Publication number: 20190169589Abstract: The disclosure provides a modified protein that is a combination of (i) an L-asparaginase and (ii) one or more (poly)peptide(s), wherein the (poly)peptide consists solely of proline and alanine amino acid residues, and methods of preparation and use thereof.Type: ApplicationFiled: December 19, 2018Publication date: June 6, 2019Applicants: XL-Protein GmbH, Jazz Pharmaceutical Ireland LimitedInventors: Lars Friedrich, Anne O'Donnell
-
Patent number: 10213400Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.Type: GrantFiled: January 12, 2018Date of Patent: February 26, 2019Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITEDInventor: Mark Eller
-
Patent number: 10174302Abstract: The disclosure provides a modified protein that is a combination of (i) an L-asparaginase and (ii) one or more (poly)peptide(s), wherein the (poly)peptide consists solely of proline and alanine amino acid residues, and methods of preparation and use thereof.Type: GrantFiled: August 7, 2017Date of Patent: January 8, 2019Assignees: XL-protein GmbH, Jazz Pharmaceuticals Ireland LimitedInventors: Lars Friedrich, Anne O'Donnell
-
Publication number: 20180371446Abstract: The disclosure provides a modified protein that is a combination of (i) an L-asparaginase and (ii) one or more (poly)peptide(s), wherein the (poly)peptide consists solely of proline and alanine amino acid residues, and methods of preparation and use thereof.Type: ApplicationFiled: August 7, 2017Publication date: December 27, 2018Applicants: XL-protein GmbH, Jazz Pharmaceuticals Ireland LimitedInventors: Lars Friedrich, Anne O'Donnell
-
Patent number: 9555017Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.Type: GrantFiled: August 7, 2015Date of Patent: January 31, 2017Assignee: Jazz Pharmaceuticals Ireland LimitedInventors: Clark P. Allphin, Michael DesJardin